Is Sacituzumab govitecan covered by medical insurance?

Sacituzumab govitecan is a cancer drug used to treat adults with triple-negative breast cancer. In triple-negative breast cancer, the cancer cells do not have receptors (targets) for certain hormones on their surface, nor do they have abnormally high levels of the HER2 protein (HER2-negative). In these patients, this drug is used when the cancer cannot be removed with surgery because the cancer has spread to areas outside the breast (locally advanced) or to other parts of the body (metastatic). It is used in patients who have had two or more previous systemic (systemic) treatments, including at least one for advanced disease.

Gosatuzumab contains the active substancesacituzumab govitecan and is also used to treat breast cancer when the cancer cells have receptors for certain hormones on their surface (HR positive) and are HER2 negative. Gosatuzumab is also used to treat breast cancer. It is used in patients who have received endocrine therapy (hormone therapy) and two or more systemic therapies when their cancer cannot be removed with surgery or is metastatic.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.